EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advanced therapies in Parkinson’s disease: an individualized approach to their indication

Nils Schröter iD, Bastian E A Sajonz, Wolfgang H Jost, Michel Rijntjes, Volker A Coenen, Sergiu Groppa

Journal of Neural Transmission · 2024-11 · 131 (11) · 1285-1293

DOI: 10.1007/s00702-024-02773-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neural Transmission, online erschienen am 13.04.2024. Verfasst von Nils Schröter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Clinical Neuroscience, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. nils.schroeter@uni…. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Antiparkinson Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Freiburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep brain stimulation (DBS) are used to treat Parkinson’s disease with insufficient symptom alleviation under intensified pharmacotherapy. These DAT significantly differ in their efficacy profiles, indication, invasiveness, contraindications, and potential side effects. Usually, the evaluation of all these procedures is conducted simultaneously at the same point in time. However, as disease progression and symptom burden is extremely heterogeneous, clinical experience shows that patients reach the individual milestones for a certain therapy at different points in their disease course. Therefore, advocating for an individualized therapy evaluation for each DAT, requiring an ongoing evaluation. This necessitates that, during each consultation, the current symptomatology should be analyzed, and the potential suitability for a DAT be assessed. This work represents a critical interdisciplinary appraisal of these therapies in terms of their individual profiles and compares these DAT regarding contraindications, periprocedural considerations as well as their efficacy regarding motor- and non-motor deficits, supporting a personalized approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDeep Brain StimulationAntiparkinson AgentsHumansPrecision MedicineCarbidopaLevodopa

Stichwörter der Autor:innen

CSAIDBSDevice aided therapiesLCIGParkinson’s disease

Substanzen

Antiparkinson AgentsCarbidopaLevodopa

Autor:innen und Institutionen

  • Department of Neurology and Clinical Neuroscience, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. nils.schroeter@uniklinik-freiburg.de.
  • Department of Stereotactic and Functional Neurosurgery, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Parkinson-Klinik Ortenau, Wolfach, Germany.
  • Department of Neurology and Clinical Neuroscience, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Center of Deep Brain Stimulation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Section of Movement Disorders and Neurostimulation, Department of Neurology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

ORCID-Profile: Nils Schröter

Förderung

  • Universitätsklinikum Freiburg

Zitieren

APA

Schröter, N., Sajonz, B. E. A., Jost, W. H., Rijntjes, M., Coenen, V. A., & Groppa, S. (2024). Advanced therapies in Parkinson’s disease: an individualized approach to their indication. Journal of Neural Transmission, 131(11), 1285-1293. https://doi.org/10.1007/s00702-024-02773-3

Vancouver

Schröter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S. Advanced therapies in Parkinson’s disease: an individualized approach to their indication. Journal of Neural Transmission. 2024;131(11):1285-1293. doi:10.1007/s00702-024-02773-3

BibTeX
@article{Schrter2024,
  author = {Schröter, Nils and Sajonz, Bastian E A and Jost, Wolfgang H and Rijntjes, Michel and Coenen, Volker A and Groppa, Sergiu},
  title = {Advanced therapies in Parkinson’s disease: an individualized approach to their indication},
  journal = {Journal of Neural Transmission},
  year = {2024},
  volume = {131},
  number = {11},
  pages = {1285--1293},
  doi = {10.1007/s00702-024-02773-3}
}
Kostenlos starten →